Vienna-based PIUR IMAGING, a medical gadget firm innovating AI-powered tomographic 3D ultrasound, at present introduced the profitable closing of a €5.6 million progress capital funding spherical.
The spherical was led by Aescuvest Capital Companions, a number one healthcare funding in Germany.
“Ultrasound is likely one of the most dear imaging modalities – versatile, protected, and reasonably priced. However its best limitation stays user-dependency, as most conclusions are drawn from 2D slices that modify by operator,” stated Frederik Bender, Managing Director & CEO of PIUR IMAGING. “By including a 3rd dimension, we get rid of a lot of that variability – shifting from subjective snapshots to complete, organ-level imaging that allows AI to carry out extra constant and dependable evaluation.
“This funding permits us to deliver this imaginative and prescient to scale. It empowers us to develop our industrial footprint, particularly within the U.S., increase our product integration with world ultrasound leaders, and proceed creating medical purposes that enhance affected person outcomes. We’re not simply including know-how – we’re altering the usual of care.”
Based in 2014, PIUR IMAGING is an ISO-13485 licensed and FDA-cleared medical gadget firm, specialising in superior tomographic 3D ultrasound options. Their mission is to enhance diagnostic workflows and improve affected person care by providing progressive add-on options for current ultrasound units, empowering clinicians with correct, reproducible imaging for optimum affected person outcomes.
The corporate’s proprietary sensor reportedly transforms normal 2D ultrasound programs into high-performance 3D imaging platforms – enabling total organs and anatomical buildings to be captured in a single scan. Coupled with AI-based picture evaluation and volumetric measurements, this development empowers clinicians to ship quicker, extra goal, and extra reproducible diagnoses throughout a broad vary of medical purposes.
“PIUR’s method is elegant in its simplicity. Relatively than reinventing the wheel, they unlock new worth from current ultrasound programs with a seamless add-on answer,” stated Christoph Bartoschek, Funding Principal at Aescuvest Capital Companions. “This lowers the adoption barrier considerably – customers perceive it instantly, and the medical advantages are clear.”
Following current FDA clearance and the institution of a U.S. subsidiary, the brand new funding will gasoline the corporate’s industrial enlargement, notably in the US.
Development will probably be pushed by two core merchandise: PIUR tUS Infinity , a vendor-neutral add-on that turns any current 2D ultrasound right into a 3D gadget, and PIUR tUS inside, an built-in answer immediately embedded into choose GE HealthCare LOGIQ scanners.
“What excites us as traders is the readability of the worth proposition and the corporate’s sturdy basis. PIUR has already constructed a loyal buyer base within the DACH area, signed agreements with revered companions within the imaging ecosystem, and assembled a crew with a centered imaginative and prescient for scaling throughout medical indications and geographies.
“The current FDA clearance of the tUS inside makes this a really perfect time to take a position, aligning completely with our technique of focusing on alternatives approaching key regulatory milestones,” Bartoschek added.
As healthcare programs world wide search to enhance diagnostic entry and effectivity, PIUR’s tomographic 3D ult rasound presents a probably transformative reply.
